RxDoctor Payments Data

Shehzad Basaria, MD

Endocrinology, Diabetes & Metabolism · Boston, MANPI 1699730101

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $800 of the $800 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Pfizer. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MA, where the typical reported total is $583.

$800in general payments, 2019–2025

Across 2 payments — averaging $400.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$800
$549,774in research payments, 2019–2025

Across 7 payments — averaging $78,539 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$272K
  • Endo USA, Inc.$141K
  • Endo Pharmaceuticals Inc.$136K

What the payments were for

  • Consulting fees$800100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$800

How this compares

$800 in reported general payments places this provider in the 50th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts

Medicare billing

Part B allowed, 2024
$21,400
Medicare patients
133
Services billed
157

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Testosterone32$3,675
Risedronate Sodium21$1,197
Alendronate Sodium84$995

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →